Baudax Bio Inc. (NASDAQ: BXRX) is 10.89% higher on its value in year-to-date trading and has touched a low of $0.97 and a high of $4.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BXRX stock was last observed hovering at around $1.09 in the last trading session, with the day’s gains setting it 0.03% off its average median price target of $5.00 for the next 12 months. It is also 81.33% off the consensus price target high of $6.00 offered by 3 analysts, but current levels are 62.67% higher than the price target low of $3.00 for the same period.
Currently trading at $1.12, the stock is -2.78% and -14.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.86 million and changing 2.75% at the moment leaves the stock -41.38% off its SMA200. BXRX registered -67.16% loss for a year compared to 6-month loss of -13.18%. The firm has a 50-day simple moving average (SMA 50) of $1.4086 and a 200-day simple moving average (SMA200) of $1.5549.
The stock witnessed a -8.94% gain in the last 1 month and extending the period to 3 months gives it a -17.04%, and is 5.66% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.03% over the week and 7.13% over the month.
Baudax Bio Inc. (BXRX) has around 57 employees, a market worth around $79.34M and $0.50M in sales. Distance from 52-week low is 15.46% and -77.37% from its 52-week high. The company has generated returns on investments over the last 12 months (1335.50%).
Baudax Bio Inc. (BXRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Baudax Bio Inc. (BXRX) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Baudax Bio Inc. is expected to release its quarterly report on 08/09/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $630k over the same period.The EPS is expected to shrink by -12.90% this year, but quarterly earnings will post 2,218.50% year-over-year.
Baudax Bio Inc. (BXRX) Top Institutional Holders
49 institutions hold shares in Baudax Bio Inc. (BXRX), with 587.79k shares held by insiders accounting for 0.84% while institutional investors hold 17.41% of the company’s shares. The shares outstanding are 70.14M, and float is at 62.58M with Short Float at 6.97%. Institutions hold 17.26% of the Float.
The top institutional shareholder in the company is Armistice Capital, LLC with over 3.5 million shares valued at $3.54 million. The investor’s holdings represent 4.99% of the BXRX Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 0.5 million shares valued at $0.5 million to account for 0.71% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 0.42 million shares representing 0.60% and valued at over $0.43 million, while Gsa Capital Partners Llp holds 0.32% of the shares totaling 0.22 million with a market value of $0.22 million.
Baudax Bio Inc. (BXRX) Insider Activity
A total of 15 insider transactions have happened at Baudax Bio Inc. (BXRX) in the last six months, with sales accounting for 3 and purchases happening 12 times. The most recent transaction is an insider purchase by Casten Richard S, the company’s Chief Financial Officer. SEC filings show that Casten Richard S bought 25,000 shares of the company’s common stock on Mar 15 at a price of $1.41 per share for a total of $35180.0. Following the purchase, the insider now owns 0.13 million shares.